Year: 2025
Type: article
Abstract: Neurological diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), have long posed significant health challenges due to their complex pathogenesis and the profound impact they have on patients' quality of life. Traditional treatments often fall short of providing radical cures, particularly hindered by barriers like the blood-brain barrier (BBB). In recent years, biopharmaceuticals—leveraging advanced technologies such as genetic engineering and cell engineering—have emerged as promising therapeutic alternatives. This paper summarizes biopharmaceutical strategies for treating these two neurological diseases, analyzes the advantages and disadvantages of biopharmaceutical technologies in disease treatment, and provides a detailed description of the pathogenesis and clinical manifestations of these diseases. The conclusion highlights that biopharmaceutical technology has become one of the most effective means for treating neurological diseases, but it still faces obstacles and limitations. Future advancements require technological improvements and clinical trials to enhance treatment success rates and refine preventive measures for neurological diseases.
Source: Theoretical and Natural Science
Author: Zixin Wang
Institution: Beijing Foreign Studies University
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4410899480